Last reviewed · How we verify
A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics
PPI-1011 is being developed as a docosahexaenoic acid (DHA) containing plasmalogen precursor with good long-term stability, specifically for the treatment of rhizomelic chondrodysplasia punctata (RCDP), which is an ultra rare type of peroxisomal biogenesis disorder (PBD). The goal of treatment with PPI-1011 is to increase the levels of plasmalogens within circulation and tissues, with the hope that this will normalize plasmalogen levels in the body and result in clinical improvement to patients. The present study is a first-in-human (FIH), phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of PPI-1011 administered orally to healthy subjects. The study consists of 5 planned single-dose cohorts (n = 8 per cohort, total randomized 6 active: 2 placebo) with sentinel design. Following a review of the safety and PK data by the safety review committee and submission to Health Canada the study will be expanded to include 2 planned multiple-dose cohorts (n = 8 per cohort, total randomized 6 active: 2 placebo).
Details
| Lead sponsor | MED-LIFE DISCOVERIES LP |
|---|---|
| Phase | PHASE1 |
| Status | UNKNOWN |
| Enrolment | 56 |
| Start date | Mon May 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Nov 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Rhizomelic Chondrodysplasia Punctata
Interventions
- PPI-1011
- Placebo
Countries
Canada